132 related articles for article (PubMed ID: 17476677)
1. Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab.
Reumaux D; Bardin N; Colombel JF; Dignat-George F; Duthilleul P; Vermeire S
Inflamm Bowel Dis; 2007 Oct; 13(10):1315-7. PubMed ID: 17476677
[No Abstract] [Full Text] [Related]
2. Infliximab dose intensification by shortening infusion intervals.
Magro F; Bastos R; Marques M; Costa Santos C
Inflamm Bowel Dis; 2008 Mar; 14(3):432-4. PubMed ID: 18022873
[No Abstract] [Full Text] [Related]
3. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
4. Systemic amyloidosis with Crohn's disease treated with infliximab.
Park YK; Han DS; Eun CS
Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
[No Abstract] [Full Text] [Related]
5. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.
Angelucci E; Cocco A; Viscido A; Caprilli R
Inflamm Bowel Dis; 2008 Mar; 14(3):435-6. PubMed ID: 18050300
[No Abstract] [Full Text] [Related]
6. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
7. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
Korzenik JR
Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
[TBL] [Abstract][Full Text] [Related]
8. Early combined immunosuppression in Crohn's disease.
Lees CW; Satsangi J
Lancet; 2008 Jun; 371(9629):1995; author reply 1996-7. PubMed ID: 18555905
[No Abstract] [Full Text] [Related]
9. Treatment of vulval Crohn's disease with infliximab.
Preston PW; Hudson N; Lewis FM
Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
[No Abstract] [Full Text] [Related]
11. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.
Katz L; Gisbert JP; Manoogian B; Lin K; Steenholdt C; Mantzaris GJ; Atreja A; Ron Y; Swaminath A; Shah S; Hart A; Lakatos PL; Ellul P; Israeli E; Svendsen MN; van der Woude CJ; Katsanos KH; Yun L; Tsianos EV; Nathan T; Abreu M; Dotan I; Lashner B; Brynskov J; Terdiman JP; Higgins PD; Chaparro M; Ben-Horin S
Inflamm Bowel Dis; 2012 Nov; 18(11):2026-33. PubMed ID: 22294554
[TBL] [Abstract][Full Text] [Related]
12. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
13. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
14. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
15. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
[No Abstract] [Full Text] [Related]
16. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Barthel HR; Gille T; Halbsguth A; Kramer M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
[No Abstract] [Full Text] [Related]
18. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
Teichgräber U; Atreya I; Atreya R; Schwab M; Neurath MF
Inflamm Bowel Dis; 2013; 19(4):E54-5. PubMed ID: 22532373
[No Abstract] [Full Text] [Related]
19. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab.
Di Sabatino A; Rosado MM; Cazzola P; Biancheri P; Tinozzi FP; Laera MR; Cantoro L; Vanoli A; Carsetti R; Corazza GR
Inflamm Bowel Dis; 2008 May; 14(5):591-6. PubMed ID: 18240280
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease.
Levesque BG; Sandborn WJ
Inflamm Bowel Dis; 2011 Jun; 17(6):1443-4. PubMed ID: 21560204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
